No Data
Koei Tecmo, Komeda ETC (addition) Rating
Upgrade - Bullish Code Stock Name Brokerage Firm Previous After---------------------------------------------------- <8968> Fukuoka REIT Mizuho "Hold" "Buy" Downgrade - Bearish Code Stock Name Brokerage Firm Previous After---------------------------------------------------- <3481> Mitsubishi Logistics Mizuho "Buy" "Hold" <7752> Ricoh Daiwa
Astellas Pharma (ALPMY) Upgraded to Strong Buy: What Does It Mean for the Stock?
Astellas Pharma Reports Record Revenue and Growth
Astellas Pharma Core Profit Surges 198% in Fiscal 2024
Spot information for individual stocks (1)
Astellas Pharma <4503.T> continues to rise. The core operating profit Financial Estimates for the fiscal year ending March 2026 (consolidated) is expected to be 410 billion yen (a 5% increase from the previous year). Anritsu <6754.T> surges sharply. The consolidated operating profit Financial Estimates for the fiscal year ending March 2026 is expected to be 15 billion yen (a 24% increase from the previous year). AGP <9377.T> hits the upper limit in a buying trend. JAL <9201.T> proposed a stock merger as part of its privatization plan. Fujitsu <6755.T> (under supervision) remains steady. A TOB (public stock purchase) by Paloma Reem Holdings is underway.
April 28th [Today's Investment Strategy]
[Fisco Selected Stocks]【Material Stocks】Hokkan Holdings <5902> 1,699 yen (4/25) Engaged in food cans, PET bottles, and filling business. The profit forecast for the fiscal year ending March 2025 has been revised upward. The estimated operating profit is 4.5 billion yen (up 2.5% from the previous year). This is an upward revision of about 9% from the previous financial estimates, resulting in a projected increase in profit. Revenue is expected to be lower than the previous forecast, but due to cost reductions in factory expenses and Logistics costs, profit has been upwardly revised. The year-end Dividends have been set at 70 yen.
